ProQR Therapeutics N.V.

Summary

ProQR Therapeutics N.V., based in Leiden, develops medicines that aim to edit RNA, the temporary messages cells use to make proteins. Its Axiomer platform recruits an enzyme already present in the body to change a selected letter in that message. The intended change is to RNA, not a permanent rewrite of the patient’s DNA.

The company is still developing and testing its therapies. It has no approved product from this platform. Its business combines an internal pipeline with research partnerships, including work with Eli Lilly. Reported revenue comes from collaboration arrangements, not routine sales of an approved medicine.

Customer value

• Potential treatment options: RNA editing aims to change disease-related protein activity in ways that could help patients if clinical studies establish a useful effect.
• A platform for partners: Pharmaceutical collaborators can use the technology and ProQR’s expertise to develop programmes against selected targets.
• A different route to intervention: Editing an RNA message offers a mechanism distinct from replacing a gene. The clinical value and appropriate dosing still need to be demonstrated.

What sets it apart

Axiomer is designed to recruit the body’s own ADAR enzymes, which can convert a specific RNA letter and alter how the message is read. The company is developing the chemistry and delivery needed to make that process work at a chosen target.

Laboratory activity and early target engagement are steps in development. They do not establish that a treatment improves a patient’s health or will receive approval.

Growth plans

ProQR is advancing its own clinical programmes, including AX-0810 and AX-0811, while continuing collaboration work. Its 2026 updates describe early clinical progress and financing to support the pipeline.

The next stages involve collecting safety, dosing and biological-effect data. The cash balance helps fund those studies; it is not the same thing as revenue or evidence that a medicine is commercially ready.